脓毒症急性肾损伤诊断标准研究进展

Advance on biomarkers for the diagnosis of sepsis combined with acute kidney injury

尽管治疗脓毒症(Sepsis)的医疗技术快速发展,但是脓毒症患者病死率至今仍居高不下,脓毒症依然是重症监护病房(ICU)患者的主要死亡原因之一。而脓毒症并发急性肾损伤(AKI)时,患者病死率可高达67.3%,同时机械通气时间明显延长、住院时间显著增加、肾脏替代治疗(RRT)使用率明显上升,医疗费用也因此显著增加。因此,如何早期诊断脓毒症AKI并有效抑制其向急性肾衰竭方向进展,降低患者临床病死率和医疗费用,已经成为重症医学领域临床研究的重要内容之一。然而目前临床上对脓毒症AKI早期诊断仍缺乏相应有效的诊断标记物。本文对脓毒症急性肾损伤的早期诊断标记物综述如下。

With the rapid development of medical technology, the fatality rate of patients with sepsis remains high, and sepsis still constitutes one of the causes for the death of patients in Intensive Care Unit. When sepsis is com-bined with acute kidney injury （AKI）, the mortality rate of the patients can reach 67.3%, and the time of mechanical ventilation is significantly prolonged, with the length of hospital stay significantly increased, the usage rate of renal re-placement therapy significantly promoted, and hospitalization costs remarkably increased. Therefore, how to diagnose sepsis combined with AKI early, effectively prevent AKI from developing into acute kidney failure, and decrease the hospitalization costs and the clinical fatality rate of patients have become one of the important points in the clinical re-search of Intensive Care Unit. However, the early diagnosis of sepsis combined with AKI still lacks corresponding ef-fective diagnostic markers. This paper depicts the early diagnostic markers for sepsis combined with AKI.